6,395,768, covers the use of indole-3-propionic acid compounds to inhibit the deposition of toxic amyloid
fibrils that lead to Alzheimer's disease as well as prevent damage from oxidative stress. Mindset is the
worldwide exclusive licensee of this platform patent.
OXIGONŽ is currently in preclinical development and is scheduled to enter clinical development early
next year. It was selected for the next clinical trial by the prestigious Alzheimer's Disease Cooperative
Study (ADCS). The ADCS is a consortium of leading clinical investigators chartered by the National
Institute of Aging in the United States to conduct clinical trials for promising new Alzheimer's therapies.
The ADCS plans to sponsor the first trial in Alzheimer's patients with OXIGONŽ.
The preclinical development of OXIGONŽ is also supported by grants from the National Institute of Aging
and from the Institute for the Study of Aging, a private philanthropic organization in New York, whose
mission is to catalyze and fund drug discovery and development, for the prevention and treatment of
cognitive aging, Alzheimer's disease and related disorders.
"The US patent reinforces our leadership in developing innovative therapies for the treatment of
Alzheimer's Disease, by providing strong protection for our core technology platform. Innovative therapies
based on this technology, could exert strong therapeutic effects through a unique dual mode of action,
that targets key mechanisms in the pathogenesis of Alzheimer's disease, as well as other major diseases
including Parkinson's disease, motor neuron disease and stroke," said Dr. Daniel Chain, President and
CEO of Mindset BioPharmaceuticals.
About Mindset
About Alzheimer's Disease
Drugs currently available for the treatment of the disease appear to affect the symptoms of the disease,
rather than the underlying pathogenesis. There is an urgent need to rethink the goals of Alzheimer's
disease treatment and to create drugs that will not only alleviate cognitive problems associated with the
malady's early stages, but more importantly, slow progression and even prevent the disease altogether.
U.S. Patent Reinforces Mindset's Leadership in Alzheimer's Disease Drug Discovery
Mindset BioPharmaceuticals (USA) Inc., announced that New York University School of Medicine, and the
University of South Alabama have been issued a U.S. patent relating to OXIGONŽ, the company's
industry-leading product for the treatment of Alzheimer's disease. The patent, issued on May 28, 2002 No.
Mindset BioPharmaceuticals (USA) Inc. is a privately-held biotechnology company with a Jerusalem
based subsidiary, carrying out research and development. Mindset is lead by a world-class scientific team
and is backed by two leading investment groups, MPM Capital and Clal Biotechnology Industries.
Mindset is emerging as an innovative leader in developing new therapeutic products for the treatment of
Alzheimer's disease and other neurodegenerative diseases. The company has two major therapeutic
programs: a unique small molecule pharmacological approach, which targets two key mechanisms that
underlie the pathogenesis of Alzheimer's disease and an immunotherapeutic program based on
immunizing patients against the harmful affects of Alzheimer's toxin, the so-called amyloid protein.
Mindset also has developed a unique platform for lead drug candidate selection, and optimization, using
transgenic mouse models to study drugs effects in Alzheimer's disease and other neurodegenerative
disorders including cognitive impairment. MindGenix Inc., a subsidiary of Mindset based in Albany, NY,
offers contract research in the transgenic models.
Alzheimer's disease is a disorder, affecting approximately 8 million Europeans and Americans and the
number is expected to rise dramatically with an increasing elderly population. With symptoms ranging from
forgetfulness to language difficulties, from changes in mood and personality to loss of insight culminating
in the destruction of brain cells, this devastating condition is one of the leading causes of death and
disability in the western world.